BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12581249)

  • 1. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
    Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
    Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
    Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
    Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA; Remotti H; Baergen RN; Altorki NK
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of adenocarcinoma arising in Barrett's esophagus.
    Hoff SJ; Sawyers JL; Blanke CD; Choy H; Stewart JR
    Ann Thorac Surg; 1998 Jan; 65(1):176-80; discussion 180-1. PubMed ID: 9456113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
    Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
    Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia.
    Iravani S; Zhang HQ; Yuan ZQ; Cheng JQ; Karl RC; Jove R; Coppola D
    Hum Pathol; 2003 Oct; 34(10):975-82. PubMed ID: 14608530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
    Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
    J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's esophagus: cancer and molecular biology.
    Gibson MK; Dhaliwal AS; Clemons NJ; Phillips WA; Dvorak K; Tong D; Law S; Pirchi ED; Räsänen J; Krasna MJ; Parikh K; Krishnadath KK; Chen Y; Griffiths L; Colleypriest BJ; Farrant JM; Tosh D; Das KM; Bajpai M
    Ann N Y Acad Sci; 2013 Oct; 1300():296-314. PubMed ID: 24117650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence.
    Goldblum JR; Rice TW
    Mod Pathol; 1995 Oct; 8(8):866-9. PubMed ID: 8552577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
    Shimizu D; Vallböhmer D; Kuramochi H; Uchida K; Schneider S; Chandrasoma PT; Shimada H; DeMeester TR; Danenberg KD; Peters JH; DeMeester SR; Danenberg PV
    Int J Cancer; 2006 Aug; 119(4):765-70. PubMed ID: 16550596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation.
    Cen P; Correa AM; Lee JH; Maru D; Anandasabapathy S; Liao Z; Hofstetter WL; Swisher SG; Komaki R; Ross WA; Vaporciyan A; Ajani JA
    Dis Esophagus; 2009; 22(1):32-41. PubMed ID: 19021684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.